Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...3536373839404142434445...266267»
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Yervoy (ipilimumab) / Ono Pharma, BMS
    Severe nephrotoxicity with ipilimumab - attempted rechallenging under tocilizumab () -  Jul 3, 2023 - Abstract #WCD2023WCD_6105;    
    KEY MESSAGE: The rechallenge with ipilimumab, in patients with severe nephropathy as a previous adverse effect, may be necessary because it is the only therapeutic alternative. The use of tocilizumab associated with low doses of systemic corticosteroids may be an important therapeutic weapon in preventing new grade III and IV adverse effects
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Pembrolizumab-induced mucocutaneous lichen planus () -  Jul 3, 2023 - Abstract #WCD2023WCD_5269;    
    The use of tocilizumab associated with low doses of systemic corticosteroids may be an important therapeutic weapon in preventing new grade III and IV adverse effects BACKGROUND: Pembrolizumab, a human programmed death receptor-1 (PD-1)
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Primary cutaneous malignant melanoma mimicking nevus spilus () -  Jul 3, 2023 - Abstract #WCD2023WCD_4113;    
    KEY MESSAGE: Nevus spilus-like flat lesions around primary malignant melanoma were all malignant lesions. These speckled lesions were probably spread by in situ invasion from the primary nodule
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition, Metastases:  Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. (Pubmed Central) -  Jul 3, 2023   
    This retrospective study showed that immune checkpoint inhibitors-based treatment for renal cell carcinoma exhibited less marked effects in female than in male patients. Thus, sex may be an important factor for decision-making on systemic therapy as renal cell carcinoma treatment, although further studies are required to validate the present findings.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, PD(L)-1 Biomarker, IO biomarker, Surgery:  PD-1 blockade attenuates surgery-mediated immunosuppression and boosts Th1 immunity perioperatively in oesophagogastric junctional adenocarcinoma. (Pubmed Central) -  Jun 30, 2023   
    Of note, the addition of nivolumab or ipilimumab attenuated the surgery-mediated suppression of lymphocyte cytotoxicity, demonstrated by a significant increase in tumour cell killing and an increase in the frequency of Th1-like cells and Th1 cytokine production. These findings support the hypothesis of a surgery-mediated suppression in Th1-like cytotoxic immunity and highlights a rationale for the use of ICB within the perioperative setting to abrogate tumour-promoting effects of surgery and ameliorate the risk of recurrence.
  • ||||||||||  Kimmtrak (tebentafusp) / Immunocore, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Metastases:  Determinants of overall survival in patients with metastatic uveal melanoma. (Pubmed Central) -  Jun 29, 2023   
    Factors such as extrahepatic-only metastases, better baseline performance status, and female sex contributed to a more than 2-fold reduction in death risk. These findings highlight the potential of immunotherapy in treating metastatic uveal melanoma.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal, Metastases:  Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma. (Pubmed Central) -  Jun 27, 2023   
    This cohort study of patients with advanced melanoma receiving first-line ICI therapy suggests that TFS represents a patient-centric, informative end point. Patients treated with combination nivolumab-ipilimumab spent more time alive and free from systemic anticancer therapy than those treated with anti-PD-1 monotherapy alone.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, IO biomarker:  IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (clinicaltrials.gov) -  Jun 23, 2023   
    P2,  N=56, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Aug 2023 --> Apr 2023 Trial completion date: May 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2022
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion, Trial completion date:  Radiation and Combination Immunotherapy for Melanoma (clinicaltrials.gov) -  Jun 23, 2023   
    P2,  N=4, Completed, 
    Trial completion date: May 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Dec 2022 Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2022
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma (clinicaltrials.gov) -  Jun 22, 2023   
    P2,  N=10, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2022 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  Drug Screening Using Novel IMD in Renal Cell Carcinoma (clinicaltrials.gov) -  Jun 22, 2023   
    P1,  N=5, Recruiting, 
    Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2025 Not yet recruiting --> Recruiting | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2023 --> Mar 2024
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. (Pubmed Central) -  Jun 22, 2023   
    More than ten years after the approval of ipilimumab, immune checkpoint inhibitors (ICIs) against PD-1 and CTLA-4 have been established as the most effective treatment for locally advanced or metastatic melanoma, achieving durable responses either as monotherapies or in combinatorial regimens...The recent approval of anti-LAG-3 ICI, relatlimab, in combination with nivolumab for metastatic disease, has capitalized on the extensive research in the field and has highlighted the potential for further improvement of melanoma prognosis by synergistically blocking additional immune targets with new ICI-doublets, antibody-drug conjugates, or other novel modalities...Beginning from their immunomodulatory properties as co-inhibitory or co-stimulatory receptors, we present all therapeutic modalities targeting these molecules that have been tested in melanoma treatment either in preclinical or clinical settings. Better understanding of the checkpoint-mediated crosstalk between melanoma and immune effector cells is essential for generating more effective strategies with augmented immune response.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Biomarker, P2 data, Clinical Trial,Phase II, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial. (Pubmed Central) -  Jun 21, 2023   
    Better understanding of the checkpoint-mediated crosstalk between melanoma and immune effector cells is essential for generating more effective strategies with augmented immune response. Prospective validation of this liquid biomarker triad is needed to molecularly define HER2+ EGA patient subsets with different needs in the first-line systemic treatment setting.
  • ||||||||||  Journal:  2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma. (Pubmed Central) -  Jun 19, 2023   
    Finally, the activity of cabozantinib as second-line therapy after progression to ICI-based combinations was prospectively assessed. This 2023 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized management of mRCC.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids. (Pubmed Central) -  Jun 19, 2023   
    Patients with symptomatic MBM derive only modest benefit from combination immunotherapy treatment. Nevertheless, those with disease response have the potential to derive long-term benefit, justifying ipilimumab plus nivolumab in this group in the absence of other more effective treatment options.
  • ||||||||||  Retrospective data, Review, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. (Pubmed Central) -  Jun 19, 2023   
    Hence, our work supports the use of PD-1 inhibition in this group of patients with high unmet medical need. Relatlimab/nivolumab showed similar PFS and ORR compared to ipilimumab/nivolumab, with a trend for a better safety profile.